Edgewise Therapeutics (EWTX) Share-based Compensation (2020 - 2026)

Edgewise Therapeutics (EWTX) has 7 years of Share-based Compensation data on file, last reported at $8.7 million in Q1 2026.

• For the quarter ending Q1 2026, Share-based Compensation fell 3.8% year-over-year to $8.7 million; the trailing twelve-month figure through Mar 2026 stood at $7.5 million (down 70.46% YoY), and the FY2025 full-year result was $64.9 million, up 15.69% from the prior year.
• Share-based Compensation improved to $8.7 million in Q1 2026, from -$17.1 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $9.1 million in Q1 2025 to a low of -$17.1 million in Q4 2025.
• A 5-year average of $2.7 million and a median of $3.8 million in 2023 frame the typical range for Share-based Compensation.
• Across the five-year window, Share-based Compensation slumped 402.38% in 2023 and surged 4987.1% in 2024, its largest moves.
• Tracing EWTX's Share-based Compensation over 5 years: stood at $3.7 million in 2022, then tumbled by 402.38% to -$11.3 million in 2023, then jumped by 168.48% to $7.7 million in 2024, then slumped by 320.71% to -$17.1 million in 2025, then soared by 151.04% to $8.7 million in 2026.
• Business Quant data shows EWTX's Share-based Compensation at $8.7 million in Q1 2026, -$17.1 million in Q4 2025, and $8.1 million in Q3 2025.